Natural killer cells in chronic lymphocytic leukemia: functional impairment and therapeutic potential
M Yano, JC Byrd, N Muthusamy - Cancers, 2022 - mdpi.com
Simple Summary Natural killer (NK) cells are immune cells with potent anti-tumor and anti-
infection activity. The potential benefit of NK cell therapy against chronic lymphocytic …
infection activity. The potential benefit of NK cell therapy against chronic lymphocytic …
Anti-CD20 treatment for B-cell malignancies: current status and future directions
C Klein, C Jamois, T Nielsen - Expert Opinion on Biological …, 2021 - Taylor & Francis
Introduction The introduction of anti-CD20 monoclonal antibody therapy with rituximab in the
1990s greatly improved outcomes for patients with B-cell malignancies. Disease resistance …
1990s greatly improved outcomes for patients with B-cell malignancies. Disease resistance …
Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large B-cell lymphoma patients treated with immunochemotherapy
M Klanova, MZ Oestergaard, M Trněný… - Clinical Cancer …, 2019 - AACR
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies
(mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK …
(mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK …
[HTML][HTML] Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?
TJ Phillips, JM Michot, V Ribrag - Clinical Lymphoma Myeloma and …, 2021 - Elsevier
Although outcomes following first-line therapy for patients with indolent or aggressive non-
Hodgkin lymphoma (NHL) are continually improving, relapse is still common. Current …
Hodgkin lymphoma (NHL) are continually improving, relapse is still common. Current …
Recent research progress of chiral small molecular antitumor-targeted drugs approved by the FDA from 2011 to 2019
X Chu, Y Bu, X Yang - Frontiers in Oncology, 2021 - frontiersin.org
Chiral drugs usually contain chiral centers, which are present as single enantiomers or
racemates. Compared with achiral drugs, they have significant advantages in safety and …
racemates. Compared with achiral drugs, they have significant advantages in safety and …
Duvelisib eliminates CLL B Cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a Xenograft model
SS Chen, JC Barrientos, G Ferrer, M King-Richards… - Clinical Cancer …, 2023 - AACR
Abstract Purpose: Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have
significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the …
significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the …
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
Background Immunotherapy-based regimens have considerably improved the survival rate
of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most …
of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most …
Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine and quinazoline derivatives as potent antitumor agents
H Hu, Y Dong, M Li, R Wang, X Zhang, P Gong… - Bioorganic …, 2019 - Elsevier
Four series of novel thieno [3, 2-d] pyrimidine and quinazoline derivatives containing N-
acylhydrazone or semicarbazone were designed, synthesized, and evaluated for their …
acylhydrazone or semicarbazone were designed, synthesized, and evaluated for their …
Identification of candidate risk factor genes for human idelalisib toxicity using a collaborative cross approach
M Mosedale, Y Cai, JS Eaddy, RW Corty… - Toxicological …, 2019 - academic.oup.com
Idelalisib is a phosphatidylinositol 3-kinase inhibitor highly selective for the delta isoform that
has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma …
has shown good efficacy in treating chronic lymphocytic leukemia and follicular lymphoma …
High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto) antibody production by human plasma cells
P Tuijnenburg, DJ aan de Kerk… - European journal of …, 2020 - Wiley Online Library
Antibody production by the B cell compartment is a crucial part of the adaptive immune
response. Dysregulated antibody production in the form of autoantibodies can cause …
response. Dysregulated antibody production in the form of autoantibodies can cause …